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Summary
ACTG A5271 collected neurocognitive normative comparison test data in 2400 at-risk HIV 
seronegative participants from Brazil, India, Malawi, Peru, South Africa, Thailand and Zimbabwe. 
The participants were enrolled in strata by site (10 levels), age (2 levels), education (2 levels), and 
gender (2 levels). These data provide necessary normative data infrastructure for future clinical 
research and care in these diverse resource limited settings.
Infrastructure for conducting neurological research in resource limited settings (RLS) is limited. 
The lack of neurological and neuropsychological (NP) assessment, and normative data needed for 
clinical interpretation impede research and clinical care. Here we report on ACTG 5271, which 
provided neurological training of clinical site personnel, and collected neurocognitive normative 
comparison data in diverse settings. At 10 sites in seven RLS countries, we provided training for 
NP assessments. We collected normative comparison data on HIV- participants from Brazil 
(n=240), India (n=480), Malawi (n=481), Peru (n=239), South Africa (480), Thailand (n=240) and 
Zimbabwe (n=240). Participants had a negative HIV test within 30 days before standardized NP 
exams were administered at baseline, and 770 at six-months. Participants were enrolled in 8 strata, 
Address correspondence and reprint requests to Dr. Kevin R. Robertson, Department of Neurology, University of North Carolina, 2127 
Physician Office Building, 170 Manning Drive, Chapel Hill, NC 27599-7025, USA. kevinr@neurology.unc.edu. 
Conflicts of Interest: Dr. Thomas B. Campbell has served on advisory boards for Gilead Sciences and Cipla. The authors declare no 
further potential conflicts of interest.
HHS Public Access
Author manuscript
J Neurovirol. Author manuscript; available in PMC 2017 August 01.
Published in final edited form as:
J Neurovirol. 2016 August ; 22(4): 472–478. doi:10.1007/s13365-015-0415-2.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
gender (female and male), education (<10 years and ≥ 10 years), and age (<35 years and ≥35 
years).
Of 2400 enrolled, 770 completed the six-month follow up. As expected, significant between-
country differences were evident in all the neurocognitive test scores (p<.0001). There was 
variation between the age, gender and education strata on the neurocognitive tests. Age and 
education were important variables for all tests; older participants had poorer performance and 
those with higher education had better performance. Women had better performance on verbal 
learning/memory and speed of processing tests, while men performed better on motor tests. This 
study provides the necessary neurocognitive normative data needed to build infrastructure for 
future neurological and neurocognitive studies in diverse RLS. These normative data are a much-
needed resource for both clinicians and researchers.
Keywords
Neurocognitive assessment; normative comparison data; resource-limited; cognitive impairment; 
neuropsychological functioning
Introduction
Resource-poor, developing parts of the world continue to have the greatest burden of the 
human immunodeficiency virus type 1 (HIV-1) epidemic(Robertson et al., 2010; UNAIDS, 
updated June 2014). The central and peripheral nervous system (CNS and PNS) are directly 
impacted by HIV-1, likely through underlying effects of viral and immune factors(Zayyad & 
Spudich, 2015).
The resulting direct effects of HIV within the CNS are called HIV-Associated 
Neurocognitive Disorders (HAND)(Antinori et al., 2007), which includes the more severe 
form of HIV-associated dementia (HAD), the less severe but more prevalent HIV-associated 
minor neurocognitive disorder (MND), and asymptomatic neurocognitive impairment (ANI).
A major limitation of conducting neurocognitive research in resource limited settings is the 
lack of infrastructure(Robertson et al., 2010; Robertson, Liner, & Heaton, 2009). The lack of 
infrastructure also impedes clinical neurological care. There are no neuropsychological 
instruments commonly available in many resource limited settings. In addition, there are no 
normative comparison data which are needed to provide the basis for clinical interpretation 
and diagnoses in almost all resource limited settings(Robertson et al., 2009). Very few 
studies have gathered normative neurocognitive comparison data in resource limited settings, 
and these have usually been small convenience samples. Perhaps the most comprehensive 
study was undertaken by the World Health Organization (WHO) in the early 1990's (Maj et 
al., 1994). The WHO study assessed HIV-associated cognitive impairment in 602 HIV-
positive and 353 HIV-negative individuals in Bangkok, Thailand; Kinshasa, Zaire; Nairobi, 
Kenya; and São Paolo, Brazil, and was the first multinational study to accrue and use local 
normative data. Neurocognitive studies based in China (Heaton et al., 2008), India (Ghate et 
al., 2015; Gupta et al., 2007), and Brazil (de Almeida et al., 2013) among others, have 
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collected small HIV- neurocognitive data for individual studies using different tests and 
methods.
To address the lack of infrastructure and available normative data, ACTG 5271 study was 
designed and conducted to provide neurocognitive normative data for resource limited 
settings in 10 sites across seven countries.
Methods
Sites
ACTG 5271, the International Neurocognitive Normative Comparison Study enrolled from 
sites that participated in ACTG A5199(Robertson et al., 2011). The international ACTG 
sites that participated in A5271 were located in Rio de Janeiro, Brazil; Chennai, India; Pune, 
India; Blantyre, Malawi; Lilongwe, Malawi; Lima, Peru; Johannesburg, South Africa; 
Durban, South Africa; Chiang Mai, Thailand; and Harare, Zimbabwe. The volunteers were 
recruited at their local health clinic, voluntary counseling and testing (VCT) center, or other 
HIV testing site aligned with the primary ACTG site.
Procedures
Human subject reviews and approvals by local and country specific review boards were 
obtained at each site prior to study initiation, and written informed consent was obtained 
prior to study participation. Standardized training on the administration of the neurological 
and neuropsychological screening examinations was conducted. Site study personnel were 
trained in face-to-face meetings with the study neuropsychologist and neurologists on site. 
Study personnel were required to pass a certification examination after the training and prior 
to study initiation. In addition, written manuals and DVD video training materials were 
provided to the sites for interim training updates. Annual recertification tests were required 
of all study personnel. Rigorous data monitoring at data entry through computerized range 
checks, with follow-up data cleaning through multiple queries and replies was conducted 
throughout the duration of the study. Implausible values were queried, and confirmed or 
corrected at intervals. Statistical analyses were completed with SAS, multiple comparisons 
were not controlled for.
Participants
In order to recruit volunteers who mirror the economic, cultural, and risk factor 
epidemiology of the local HIV at-risk population, participants were recruited at their local 
health clinic, voluntary counseling and testing (VCT) center, or other HIV testing site 
aligned with the primary ACTG site.
Eligible participants were men and women 18 years or older who had documentation that 
they were HIV-1 seronegative within 30 days of study enrollment. Participants were 
excluded from participation in the study if they had any active severe psychiatric illness, 
active drug or alcohol abuse or dependence, serious illness and/or hospitalization within 14 
days of study entry, or any other condition that in the opinion of the site investigator, would 
compromise the person's ability to participate in the study, adhere to study requirements, or 
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confound the analysis or interpretation of the results of the study. Participants were enrolled 
into each stratum until the stratum sample size limits were met. Participants were serially 
asked to participate in the follow-up visit on a voluntary basis, until the 6 month follow up 
strata was filled.
Neuropsychological and Neurological examinations
Standardized neurological and neuropsychological (NP) examinations (Hopkins Verbal 
learning test – Revised, Color Trails 1 and 2, Wechsler Adult Intelligence Scale Digit 
Symbol subtest, Grooved pegboard, Timed gait, Semantic Verbal fluency, Finger tapping and 
the International HIV Dementia Scale) were administered at baseline. A subset of 
participants consented to return for a 24-week follow-up assessment to estimate practice 
effect. The neuropsychological tests chosen were from ACTG 5199 The International 
Neurological Study (Robertson et al., 2011) based on prior experience in clinical trial and 
cohort studies in the ACTG, then augmented with additional tests to meet minimal HAND 
Frascati criteria while still maintaining a short battery with the least language- and culture-
specific items. Details of the neurological examination have been reported(Robertson et al., 
2011).
Results
Demographics
Participants were enrolled in the study beginning in February 2011, and the study was closed 
to all follow up visits in October 2013. The total enrollment was 2400 participants, 770 
participating in the 6 month follow-up, and with final enrollment for each site as follows: 
Johannesburg (n=240) and Durban (n=240) in South Africa; Lima, Peru (n=239); Chiang 
Mai, Thailand (n=240); Pune (n=240) and Chennai (n=240) in India; Lilongwe (n=241) and 
Blantyre (n=240) in Malawi; Rio de Janeiro, Brazil (n=240); and Harare, Zimbabwe 
(n=240). The accrual target was 30 participants per 8 strata (gender (male/female) × age (< 
35 and >=35 years) × education (<10 and >=10 years) at each site. The demographic means 
and standard deviations for the total sample and by country are presented in Table 1.
There were 1200 (50%) females and 1200 (50%) males enrolled. The median age was 35 
years (Q1 = 26, Q3 =43), and the median educational level was 10 years (Q1= 8, Q3 = 12). 
For ethnicity/race, there were 725 (30%) Asians, 1,323 (55%) Blacks, 100 (4%) White, 1 
(0%) American Indian, 250 (10%) Other, and 1 Unknown (0%). By country, there were 240 
participants in Brazil, 480 in India, 481 in Malawi, 239 in Peru, 480 in South Africa, 240 in 
Thailand and 240 in Zimbabwe.
Neuropsychological Tests
The overall normative comparison neurocognitive test score means and standard deviations 
by stratification factors of gender, age, and education are presented in Table 2. As expected 
and stratified for, there was variation in neuropsychological performance across countries. 
For example, the overall (mean (SD)) for verbal fluency was 16.8 (5.3) and differed across 
sites (χ2 (df 6) = 815.23, p<.0001); Johannesburg 13.55 (3.79), Durban 14.42 (3.59), Lima 
21.14 (4.55), Chiang Mai 20.99 (5.39), Pune 16.38 (4.49), Chennai 17.95 (4.63), Lilongwe 
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15.41 (5.33), Blantyre 12.82 (2.95), Rio de Janeiro 19.81 (5.28), and Zimbabwe 15.46 
(3.20)). For Timed gait, the overall scores were 12.4 (2.2) and differed across sites (χ2 (df 6) 
= 420.89, p<.0001); Johannesburg 10.25 (1.42), Durban 12.45 (1.79), Lima 13.97 (3.06), 
Chiang Mai 11.36 (1.29), Pune 12.40 (1.69), Chennai 13.20 (1.66), Lilongwe 13.91 (1.78), 
Blantyre 11.77 (1.50), Rio de Janeiro 12.98 (2.81), and Zimbabwe 11.92 (1.83)).
The normative scores (means and standard deviations) for each NP test are presented for 
each site by gender, age, and education stratum in the supplemental tables.
Demographic differences
There was also variation between the age, gender and education strata. Age was an 
important variable and decreases in performance with increasing age were noted for HVLT-
R learning (χ2=83.01, p<.0001), HVLT-R delay (χ2=124.86, p<.0001), Digit Symbol 
(χ2=295.55, p<.0001), Grooved Pegboard dominant (χ2=243.58, p<.0001) and 
nondominant (χ2=232.25, p< .0001), Semantic verbal fluency (χ2=9.61, p>.005), Timed 
Gait (χ2=167.91, p<.0001), Fingertapping dominant (χ2=23.08, p<.0001) and nondominant 
(χ2=22.99, p<.0001), Color trails 1 (χ2=184.82, p<.0001) and Color trails 2 (χ2=232.33, 
p<.0001). Gender was an important variable and females had better performance on HVLT-
R learning (χ2=36.94, p<.0001), HVLT-R delayed recall (χ2=23.08, p<.0001), and Digit 
Symbol (χ2=34.47, p<.0001). Males performed better on fine motor (Fingertapping 
dominant (χ2=177.09, p<.0001) and nondominant (χ2=189.01, p<.0001)) and gross motor 
(Timed gait (χ2=351.54, p<.0001) tests. No gender differences were found for semantic 
verbal fluency, Grooved pegboard dominant and nondominant, and Color trails 1 and 2. 
Education was an important variable for all the neurocognitive tests and increasing education 
was associated with better performance on HVLT-R learning (χ2=303.37, p< .0001), HVLT 
delayed recall (χ2=204.67, p<.0001), Digit Symbol (χ2=589.67, p<.0001), Grooved 
pegboard dominant (χ2=103.02, p<.0001) and nondominant (χ2=79.72, p<.0001), Semantic 
verbal fluency (χ2=140.66, p<.0001), Timed gait (χ2=51.92, p<.0001), Fingertapping 
dominant (χ2=40.73, p<.0001), and nondominant (χ2=37.98, p<.0001), Color trails 1 
(χ2=215.68, p<.0001), and Color trails 2 (χ2=326.05, p<.0001).
We also examined within country but between site test results to see if there were in fact 
substantial differences on the neurocognitive test results. Within Malawi (Lilongwe and 
Blantyre), South Africa (Durban and Johannesburg), and India (Chennai and Pune), there 
were differences on the neurocognitive tests which were not consistently in one site's favor. 
For example, in Malawi the Blantyre site would have better performance on some tests 
(verbal learning(χ2=80.47, p<.0001, memory (χ2=32.46, p<.0001), speed of processing 
(χ2=328.60, p<.0001), and gross motor (χ2=215.11,p<.0001)) while Lilongwe would 
perform better on others (fine motor (χ2=18.15, p<.0001), executive functioning (χ2=21.85, 
p<.0001), and verbal fluency (χ2=41.40, p<.0001)). Similar results were found when 
comparing South African sites of Durban (better verbal memory (χ2=14.08, p<.0005), speed 
of processing (χ2=142.40, p<.001), and executive functioning (χ2=7.54, p<.01)) and 
Johannesburg (better fine motor (χ2=13.06, p<.0005) and gross motor skills (χ2=258.72, 
p<.0001)); as well as the comparison of Indian sites of Chennai (better verbal memory 
(χ2=48.65, p<.0001), verbal fluency (χ2=14.97, p<.0001), fine motor (χ2=106.35, p<.0001) 
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and executive functioning (χ2=5.02,p<.05)) and Pune (better fine motor speed (χ2=22.15, 
p<.0001), gross motor (χ2= 36.36, p<.0001)).
Discussion
This study provides the first large-scale multisite normative comparison data in diverse 
international resource limited settings establishing a foundation to base future 
neurocognitive research and clinical studies upon. These data fill an existing limitation and 
need in both research and clinical neuropsychological areas(Robertson et al., 2009). 
Neuropsychological tests are used for assigning impairment ratings and for diagnoses (of 
HAND for example). Appropriate normative data are necessary to place these tests results 
into context and did not exist in these settings prior to the data provided in the current study.
There were substantial variations on the neurocognitive tests between countries, 
underscoring the need for country based normative data to be available to provide the 
appropriate context for valid interpretation. Other studies have found country differences, 
including one of the first neuropsychiatric studies in resource limited settings conducted by 
the WHO (Maj et al., 1994). Additional analyses found that there were differences within 
country between sites on the neurocognitive test results. While some of these differences are 
likely related to site demographic characteristics including education and age, it is likely that 
other issues such as cultural differences, rural vs. urban living and other factors could 
account for the variance seen. It is very clear that age, education and to a lesser extent 
gender, are important variables in the variance associated with neurocognitive test 
differences, and thus necessary to control for. The stratified sample collected here provides a 
foundation to build on for future studies.
The only known treatment for HAND is antiretroviral therapy (ART). We previously 
reported the first study on the impact of ART on neuropsychological functioning and 
neurological dysfunction in HIV-1 infected people in resource-limited settings(Robertson et 
al., 2011). We found that effective ART in resource limited settings improved 
neuropsychological and neurological functioning over time(Robertson et al., 2012).
With appropriate normative data made available here, screening for neurocognitive 
impairment, and diagnosing HAND would be possible in resource limited settings. Where 
available, initiation of ART in those who screen positive or are diagnosed with HAND will 
very likely improve their long-term neurocognitive outcomes, which in turn will reduce 
mortality, increase both productivity and quality of life.
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